Recent Updates
Recently added Catalysts
CGON Positive Sentiment

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Thursday, May 15, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology, a late-stage clinical biopharmaceutical company, will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York. The event is scheduled for May 20, 2025, at 11:30 am ET, and will be accessible via a live audio webcast. This participation highlights the company's commitment to advancing treatments for bladder cancer.
Price reaction · baseline $24.17 (2025-05-14 close) · hit pre-market · clean, no other CGON news in the window
day 0 close · peak
+4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology is participating in a prominent healthcare conference.
  • The company is focused on innovative treatments for bladder cancer.
  • Management engagement in investor relations indicates transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit:www.cgoncology.com.

Contacts:MediaSarah ConnorsVice President, Communications and Patient Advocacy, CG Oncology(508) 654-2277sarah.connors@cgoncology.com

Frequently Asked Questions

When is CG Oncology's participation in the conference?

CG Oncology will participate on May 20, 2025, at 11:30 am ET.

How can I access the conference webcast?

The live audio webcast can be accessed from CG Oncology's Investor Relations section.

What is the focus of CG Oncology?

CG Oncology focuses on developing therapies for bladder cancer patients.

Where is the RBC Capital Markets Conference held?

The conference will be held in New York, NY.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer RBC Capital Markets healthcare conference biopharmaceutical
Last updated: May 15, 2025

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →